| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Jinhe Biotechnology CO., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.39 |
| 52 Week High | CN¥5.20 |
| 52 Week Low | CN¥2.91 |
| Beta | 0.44 |
| 11 Month Change | 4.28% |
| 3 Month Change | 13.44% |
| 1 Year Change | -10.22% |
| 33 Year Change | -19.60% |
| 5 Year Change | -30.21% |
| Change since IPO | -28.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002688 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.8% | -1.9% | -1.2% |
| 1Y | -10.2% | -5.0% | 3.1% |
Return vs Industry: 002688 underperformed the CN Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: 002688 underperformed the CN Market which returned 3.1% over the past year.
Price Volatility
| 002688 volatility | |
|---|---|
| 002688 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 002688 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002688's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 2,316 | Changxian Xie | www.jinhe.com.cn |
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera.
Jinhe Biotechnology CO., LTD. Fundamentals Summary
| 002688 fundamental statistics | |
|---|---|
| Market cap | CN¥3.32b |
| Earnings (TTM) | CN¥97.15m |
| Revenue (TTM) | CN¥2.26b |
34.2x
P/E Ratio1.5x
P/S RatioIs 002688 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002688 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.26b |
| Cost of Revenue | CN¥1.60b |
| Gross Profit | CN¥665.68m |
| Other Expenses | CN¥568.52m |
| Earnings | CN¥97.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 29.43% |
| Net Profit Margin | 4.30% |
| Debt/Equity Ratio | 96.3% |
How did 002688 perform over the long term?
See historical performance and comparison